Work

Cationically Modified Inhalable Nintedanib Niosomes: Enhancing Therapeutic Activity Against Non-Small-Cell Lung Cancer

Year: 2022

Type: article

Abstract: Aim: This study was designed to develop and test nintedanib-loaded niosomes as inhalable carriers for enhancing its therapeutic efficacy via localized drug accumulation and addressing issues such as low bioavailability and severe toxicity. Methods: Niosomes were prepared by thin-film hydration method and were evaluated for in vitro therapeutic effectiveness in lung cancer cells. Results: The optimized niosomal formulation displayed optimized vesicle size, controlled and extended release of drug, and efficient aerodynamic properties indicating its suitability as an aerosolized formulation. In vitro studies revealed significantly superior cytotoxicity of nintedanib-loaded niosomes which was further validated by 3D spheroids. Conclusion: These findings establish the effectiveness of niosomes as inhalable delivery carriers which could serve as a promising strategy for delivery of nintedanib to treat several lung cancers.

Source: Nanomedicine

DOI: 10.2217/nnm-2022-0045

Authors: Snehal K Shukla, Veronica Nguyen, Mimansa Goyal, Vivek Gupta

Institutions: St. John's University, Pfizer (United States)

Language: English

Topic: Inhalation and Respiratory Drug Delivery

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Heart, Lung, and Blood Institute